Aspect Biosystems Entered into a Collaboration, Development and License Agreement with Novo Nordisk to Develop Bioprinted Tissue Therapies for Diabetes and Obesity
Shots:
- Aspect to receive $75M in initial fees incl. upfront, research funding & investment in the form of a convertible note, ~$650M in future development, regulatory, commercial & sales milestones per product along with royalties on future product sales
- Novo Nordisk to get an exclusive license globally to use Aspect’s bioprinting technology for the development of ~ 4 products to treat diabetes & obesity. The collaboration will use Aspect’s bioprinting technology & Novo Nordisk’s expertise & technology in stem cell differentiation, cell therapy development & manufacturing
- The partnership's initial focus will be on developing bioprinted tissue therapies to help T1D patients, maintain normal blood glucose levels without the use of immunosuppression
Ref: Globe Newswire | Image: Novo Nordisk
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
